Provided by Tiger Trade Technology Pte. Ltd.

Day One Biopharmaceuticals Inc.

8.25
-0.0200-0.24%
Post-market: 8.20-0.0500-0.61%18:38 EST
Volume:5.43M
Turnover:45.57M
Market Cap:847.07M
PE:-5.59
High:8.73
Open:8.28
Low:8.25
Close:8.27
52wk High:13.53
52wk Low:5.64
Shares:102.68M
Float Shares:78.77M
Volume Ratio:2.19
T/O Rate:6.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4748
EPS(LYR):-1.0243
ROE:-30.16%
ROA:-18.57%
PB:1.88
PE(LYR):-8.05

Loading ...

Day One Biopharmaceuticals Reports Durable Responses With OJEMDA in Pediatric Low-Grade Glioma Trial

Reuters
·
Nov 10

Day One Announces New Ojemda™ (Tovorafenib) Data to Be Presented in Oral Session at the 2025 Society for Neuro-Oncology (Sno) Annual Meeting

THOMSON REUTERS
·
Nov 10

A NEW DAWN OF HOLISTIC WELLNESS AT THE RITZ-CARLTON SPA SINGAPORE: REDEFINING LUXURY WITH THE FUTURE OF SKINCARE

prnewswire
·
Nov 06

Day One Biopharmaceuticals Up Nearly 26%, on Pace for Largest Percent Increase Since June 2022 -- Data Talk

Dow Jones
·
Nov 06

Analysts’ Opinions Are Mixed on These Healthcare Stocks: PROCEPT BioRobotics (PRCT), Day One Biopharmaceuticals (DAWN) and Exelixis (EXEL)

TIPRANKS
·
Nov 06

Day One Biopharm Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Nov 05

Stock Track | Day One Biopharmaceuticals (DAWN) Soars 8.29% on Strong Q3 Results and Analyst Endorsement

Stock Track
·
Nov 05

Stock Track | Day One Biopharmaceuticals (DAWN) Soars 6.30% Pre-market on Strong Q3 Results and Analyst Upgrade

Stock Track
·
Nov 05

Stock Track | Day One Biopharmaceuticals (DAWN) Surges 6.30% Pre-market on Strong Q3 Results and Analyst Endorsement

Stock Track
·
Nov 05

H.C. Wainwright Sticks to Their Buy Rating for Day One Biopharmaceuticals (DAWN)

TIPRANKS
·
Nov 05

Day One Biopharmaceuticals Reports Strong Q3 2025 Growth

TIPRANKS
·
Nov 05

Day One Biopharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Nov 05

BRIEF-Day One Biopharmaceuticals Q3 EPS USD -0.19

Reuters
·
Nov 05

Day One Biopharmaceuticals reports third quarter OJEMDA net product revenue of $38.5 million

Reuters
·
Nov 05

Day One Biopharmaceuticals Inc - Raises Ojemda Full-Year 2025 Net Product Revenue Guidance to $145-$150 Mln

THOMSON REUTERS
·
Nov 05

Day One Reports Third Quarter 2025 Financial Results and Corporate Progress

THOMSON REUTERS
·
Nov 05

Day One Biopharmaceuticals Inc expected to post a loss of 29 cents a share - Earnings Preview

Reuters
·
Nov 01

Day One Biopharmaceuticals Advances Pediatric Cancer Study with Promising Drug Tovorafenib

TIPRANKS
·
Oct 28

Day One Biopharmaceuticals Inc. to Report Third Quarter 2025 Results

Reuters
·
Oct 21

JonesTrading Reaffirms Their Buy Rating on Day One Biopharmaceuticals (DAWN)

TIPRANKS
·
Oct 17